Irinotecan-Based Regimens for the Second-Line Treatment of Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A Monocentric Experience

被引：0
|
作者：
Bardasi, C. [1 ]
Caputo, F. [1 ]
Santini, C. [1 ]
Cerma, K. [1 ]
Gardini, Casadei A. [1 ]
Andrikou, K. [1 ]
Salati, M. [1 ]
Fontana, A. [1 ]
Spallanzani, A. [1 ]
Bertolini, F. [1 ]
Luppi, G. [1 ]
Gelsomino, F. [1 ]
机构：
[1] Univ Hosp Modena, Dept Oncol & Hematol, Modena, Italy
来源：
NEUROENDOCRINOLOGY | 2020年 / 110卷
关键词：
neuroendocrine carcinoma; irinotecan; survival; second line treatment; nec; chemotherapy;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H03
引用
收藏
页码：180 / 180
页数：1
相关论文
共 50 条
  • [41] Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy
    Moore, M.
    Gill, S.
    Asmis, T.
    Berry, S.
    Burkes, R.
    Zbuk, K.
    Alcindor, T.
    Jeyakumar, A.
    Chan, T.
    Rao, S.
    Spratlin, J.
    Tang, P. A.
    Rothenstein, J.
    Chan, E.
    Bendell, J.
    Kudrik, F.
    Kauh, J.
    Tang, S.
    Gao, L.
    Kambhampati, S. R. P.
    Nasroulah, F.
    Yang, L.
    Ramdas, N.
    Binder, P.
    Strevel, E.
    ANNALS OF ONCOLOGY, 2016, 27 (12) : 2216 - 2224
  • [42] SWOG S2012: Randomized phase II/III trial of first line platinum (P)/etoposide (E) with or without atezolizumab (NSC #783608) in patients with advanced or metastatic poorly differentiated extrapulmonary neuroendocrine carcinomas (NEC)
    Zhen, David Bing
    Moseley, Anna
    Chiorean, E. Gabriela
    Burgess, Earle F.
    Swisher, Elizabeth M.
    Gay, Carl Michael
    Byers, Lauren Averett
    Wistuba, Ignacio Ivan
    Mahdi, Haider
    Starr, Jason S.
    Othus, Megan
    Chae, Young Kwang
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] A phase II study of sequential Irinotecan plus cisplatin (IP) and octretide LAR as first-line treatment of metastatic or inoperable poorly differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC).
    Li, Jie
    Lu, Ming
    Lu, Zhihao
    Zhou, Jun
    Wang, Xicheng
    Li, Jian
    Li, Yan
    Zhang, Xiaotian
    Gao, Jing
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] First- and second-line treatment of metastatic colo-rectal cancer (MCRC) with high-dose irinotecan (CPT-11): A monocentric institution safety analysis of 46 patients
    Mineur, L.
    Keischer, S.
    Goubely, Y.
    Molinari, N.
    Werner, H.
    ANNALS OF ONCOLOGY, 2007, 18 : VII80 - VII81
  • [45] NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)
    Craig, Zoe
    Swain, Jayne
    Batman, Emma
    Wadsley, Jonathan
    Reed, Nicholas
    Faluyi, Olusola
    Cave, Judith
    Sharma, Rohini
    Chau, Ian
    Wall, Lucy
    Lamarca, Angela
    Hubner, R.
    Mansoor, Wasat
    Sarker, Debashis
    Meyer, Tim
    Cairns, David A.
    Howard, Helen
    Valle, Juan W.
    McNamara, Mairead G.
    BMJ OPEN, 2020, 10 (02):
  • [46] Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens
    N. Baize
    A. Abakar-Mahamat
    N. Mounier
    F. Berthier
    F. X. Caroli-Bosc
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 549 - 555
  • [47] Gemcitabine and vinorelbine as second-line therapy for non-small-cell lung cancer after prior treatment with taxanes and platinum based regimens
    Campelo, RG
    Curbera, GA
    Gallegos, I
    Quindós, M
    Dopico, D
    Reboredo, M
    Antolín, S
    LUNG CANCER, 2005, 49 : S244 - S244
  • [48] Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens
    Baize, N.
    Abakar-Mahamat, A.
    Mounier, N.
    Berthier, F.
    Caroli-Bosc, F. X.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (03) : 549 - 555
  • [49] Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan
    Kashiwa, Munenobu
    Matsushita, Ryo
    CLINICAL THERAPEUTICS, 2020, 42 (07) : 1361 - 1375
  • [50] SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC)
    Zhen, David Bing
    Mayerson, Edward
    Chiorean, E. Gabriela
    Burgess, Earle F.
    Swisher, Elizabeth M.
    Gay, Carl Michael
    Byers, Lauren Averett
    Wistuba, Ignacio Ivan
    Mahdi, Haider
    Das, Satya
    Starr, Jason S.
    Othus, Megan
    Chae, Young Kwang
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345